Abstract
Local treatment following radical prostatectomy used in prostate cancer patients with risk factors of recurrence or with biochemical recurrence and/or local recurrence consists of adjuvant and salvage radiotherapy. The postprostatectomy biochemical failure, according to some studies based on ten years of follow-up, is estimated at one-third of patients. It remains challenging to extract those patients who may benefit from implementing radiotherapy while minimizing the risk of overtreatment. Adjuvant radiotherapy is considered in a situation of the absence of biochemical recurrence with the presence of high-risk features in pathological staging defined as positive surgical margins (R1), extraprostatic extension (pT3a), or seminal vesicle invasion (pT3b) and Gleason score 8-10. Failure rate after RP is found approximately in 50% of men diagnosed with adverse pathologic features. It is recommended to implement adjuvant radiotherapy in case of very aggressive form of prostate cancer (pT3b, Gleason 8-10) without awaiting biochemical recurrence. However, salvage radiotherapy represents a therapeutic option for patients experiencing biochemical recurrence in case of no distant metastasis. Monitoring of serum PSA levels in each individual is crucial in deciding whether salvage radiotherapy is needed. The effectiveness of treatment increases along with early initiation of radiation therapy. Current guidelines developed by NCCN and EAU regard conversion of PSA from undetectable to detectable level as a sign of cancers’ recurrence. In addition, prostate-specific membrane antigen (PSMA) PET should be used as a part of modern imaging diagnostics for a precise determination of disease extent.
References
Chun F.K., Graefen M., Zacharias M. i wsp. Anatomic radical retropubic prostatectomy- long-term recurence-free survival rates for localized prostate cancer. World J Urol 2006; 24: 273–280.
Bianco F.J. Jr., Scardino P.T., Eastham J.A. Radical prostatectomy. Long-term cancer control and recovery of sexual and urinary function („trifecta”). Urology 2005; 66: 83.
Han M., Partin AW., Pound CR. i wsp. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15 year Johns Hopkins experience. Urol Clin North Am 2001; 28:555-65.
Stephenson A.J., Scardino P.T., Eastham J.A. i wsp. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715–717.
Pound CR., Partin AW., Eisenberger MA. i wsp. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-7.
Lee H.M., Solan M.J., Lupinacci P. i wsp. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (PT3B): effect of adjuvant radiotherapy. Urology 2004; 64: 84–89.
Thompson IM., Tangen CM., Paradelo J. wsp. Adjuvant radiotherapy for pathological T3N0M cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2008; 181:956-62.
Bolla M., van Poppel H., Collette L. i wsp. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–578.
Wiegel T., Bottke D., Steiner U. i wsp. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924–2930.
Thompson I.M. Jr., Tangen C.M., Paradelo J. i wsp. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329–2335.
Hackman G., Taari K., Tammela TL. i wsp. Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular extension. Eur Urol 2019; 76:586-95.
Rogers CG., Khan MA., Miller MC. i wsp. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004; 101:2549-56.
Fossati N., Karnes RJ., Colicchia M. i wsp. Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol 2018; 73:436-44.
Fossati N., Karnes RJ., Cozzarini C. i wsp. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 2016 69:728-33.
www.nccn.org
Farolfi A., Ceci F., Castellucci P. i wsp. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging 2019; 46:11-9.
www.eua.org
Fendler WP., Calais J., Eiber M. i wsp. Assessment of 68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol 2019; 5:856.
Morris MJ., Rowe SP., Gorin MA. i wsp. Diagnostic performance of 18 F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR Phase 3, multicenter study. Clin Cancer Res 2021.
Ceci F., Bianchi L., Borghesi M. i wsp. Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. Eur J Nucl Med Mol Imaging 2020; 47:136-46.
Evangelista L., Zattoni F., Cassarino G. i wsp. PET/MRI in prostate cancer: a systematic review and metaanalysis. Eur J Nucl Med Mol Imaging 2020; 48:859-73.
Preisser F., Chun FKH., Pompe RS. i wsp. Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol 2019; 18:e874.
Tendulkar DR., Agrawal S., Gao T. i wsp. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy J Clin Oncol 2016 34(30): 3648-3654.
Bartkowiak D., Bottke D., Thamm R. i wsp. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival Radiother Oncol 2016 118(1):131-5.
Bartkowiak D., Thamm R., Siegmann A. i wsp. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer Radiother Oncol 2021 154:255-259.
King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012; 84:104-11.
Ghadjar P., Hayoz S., Bernhard J. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial Clinical Trial Eur Urol. 2021 Sep;80(3):306-315.
Parker CC., Clarke NW., Cook AD. i wsp. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 2020; 396:1413-21.
Kneebone A., Fraser-Browne C., Duchesne GM. i wsp. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020; 21:1331-40.
Sargos P., Chabaud S., Latorzeff I. i wsp. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020; 21:1341-52.
Vale C.L., Fisher D., Kneebone A. i wsp. Adjuvant or rally salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020; 396:1422-31.
Shipley W.U., Seiferheld W., Lukka H.R. i wsp. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017; 376: 417–428.
Fossati N., Robesti D., Karnes R. J. i wsp. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institution Study.
Shipley W.U., Seiferheld W., Lukka H.R. i wsp. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Eng J Med 2017; 376: 417–428.
Carrrie C., Magné N., Burban-Provost P. i wsp. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer. (GETUG-AFU 16): a 112-month follow-up a phase 3, randomised trial. Lancet Oncol 2019; 20:1740-9.
Pollack A., Karrison T.G., Balogh A.G. i wsp. Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiation Therapy: The NRG Oncology/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys 2018; 102:1605.
Spratt D.E., Dess R.T., Zumsteg Z.S. i wsp. A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer. Eur Urol 2018; 73: 156–165.
Gonzalez-Moya A., Supiot S., Seegers V. i wsp. Mapping of Recurrence Sites Following Adjuvant or Salvage Radiotherapy for Prostate Cancer Patients. Front Oncol 2021; 11:787347.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2022 Letters in Oncology Science